actually I think the selling is short driven and way overdone...have been watching for about 1 year waiting to BUY and just did at 25...I was looking at AMAG originally for "Imaging" as a competitor to EPIX and vasovist and than learned about Feraheme-Fe deficiency anemia which tweeked my research. upon FDA approval and booked sales this stock will go way up on 17M shares! I see a double by this time next year if approval on time and manufacturing success!
Obama should support "Feraheme in dialysis" especially because low Fe occurs chronically in these patients and EPO is used to raise RBC's when it's often more of an Fe issue and not anemia due to low RBC...also obama should support the large number of minority patients who are covered by medicare/medicaid and have higher and more disproportionate HBP and renal disease than the general population. The cost of EPO is very high relative to this product which can be given by the local GP or right in clinic by a nurse while one waits for dialysis probably given right after!( not sure on this?)
expansion indications into OBGYN and cancer will grow demand!
IMHO, the sell off is due to Obama's plan to legalize the importation of foreign-made drugs. If passed, this may allow for direct competition from other drugs such as Injectafer(which is approved in 18 countries in Europe).
I don't actually think this will happen. Even if it does, doctors will still choose Feraheme over Injectafer based on it's safety profile.